8-K - Drugs Made In America Acquisition Corp. Ordinary Shares | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Drugs Made In America Acquisition Corp. entered into a Definitive Interim Investment and Sponsor Transition Agreement with BV Advisory Partners, LLC on March 23, 2026, issuing a $100,000 interim convertible note as the first tranche of a contemplated $500,000 financing. The proceeds are intended for expenses related to a potential business combination, and the investor has introduced a specific target opportunity involving an enterprise technology platform.

Key Takeaways

1The Company issued a $100,000 interim convertible note to BV Advisory Partners, LLC on March 23, 2026.

2The note is the first tranche of a contemplated $500,000 financing, with a second tranche of $200,000 to be made within 21 days.

3The note matures in six months, does not bear interest, and is convertible at the investor's option at a 35% discount to the post-merger market price.

4The Company agreed to use commercially reasonable efforts to provide the investor with not less than 40% of the economic benefit equivalent to sponsor-level economics.

5The investor introduced a potential business combination opportunity involving an enterprise technology platform focused on AI, ML, quantum analytics, and cybersecurity.

6The Company's sponsor entity, Drugs Made In America Acquisition LLC, is non-operational and subject to legal constraints, and the Company is pursuing a replacement sponsor.

Current Report Details

Event Type

Material Agreement+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the

Material Agreement

$100.0K$500.0K

Source Document

2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of thi

Financing

8.01

Other Events On March 23, 2026, the Company entered into the Investment Agreement with the Investor relating to a proposed financing transaction pursuant to whi

Other Event

$500.0K$200.0K$500.0K

9.01

Financial Statements and Exhibits. Exhibit Number Description 10.1 Definitive Interim Investment and Sponsor Transition Agreement 10.2 Interim Convertible Note

Exhibits Only

Transaction Details

Material Agreement

Agreement: Definitive Interim Investment and Sponsor Transition Agreement
Parties: BV Advisory Partners, LLC, Drugs Made In America Acquisition Corp. I

•$500,000 total investment commitment
•Investor to receive not less than 40% of sponsor-level economic benefit
•Exclusivity conditioned on funding
•Investor has information rights and consultation on material decisions
•Governing law: Cayman Islands

Debt / Financing

Instrument: Interim Convertible Note
Principal: 100000
Rate: None
Maturity: 2026-09-23
Use of Proceeds: Accounting expenses, audit expenses, Nasdaq compliance, legal, proxy, extension, and other regulatory and transaction-related expenses

Exhibits (3)

10.1

DEFINITIVE INTERIM INVESTMENT AND SPONSOR TRANSITION AGREEMENT

10.2

INTERIM CONVERTIBLE NOTE

8-K

CURRENT REPORT